Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

29.65 -0.33 (-1.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Travere Therapeutics Inc (NASDAQ:TVTX) Q3 2025 Earnings Soar, Fueled by FILSPARI Sales and Milestone Payments
Travere Therapeutics (TVTX) Q3 2025 earnings crush expectations, driven by strong FILSPARI sales. Revenue soared 160% year-over-year, sparking an 11.7% stock surge. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Travere Therapeutics Reports Third Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For October 30, 2025
 
Via Benzinga
Travere Therapeutics to Report Third Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
From Travere Therapeutics, Inc.
Via Business Wire
Novartis Strengthens Kidney Disease Pipeline With Promising Data
Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026. 
Via Benzinga
Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Growth Momentum and Technical Setup
Travere Therapeutics (TVTX) shows strong growth momentum with accelerating earnings and revenue. Its high technical rating and clear setup pattern offer a compelling investment case. 
Via Chartmill
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
The Analyst Verdict: Travere Therapeutics In The Eyes Of 9 Experts
 
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
Travere Shares Are Trading Higher Wednesday: What's Going On?
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Daktronics, Potbelly, CoreWeave, GameStop And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High
Shares shot higher Wednesday after the FDA eliminated a key step to a new approval for its drug. 
Via Investor's Business Daily
Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application
Via Stocktwits
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism
From Travere Therapeutics, Inc.
Via Business Wire
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing. 
Via Benzinga
Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch
The company has made a name for itself with a drug that treats a progressive kidney condition. 
Via Investor's Business Daily
Nvidia To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (6 Ratings)
 
Via Benzinga
Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
Viking Global Dumps UnitedHealth, Loads Up On Disney, McDonald's, JPMorgan, AMD In Q2 Shake-Up
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics Inc (NASDAQ:TVTX) Surpasses Q2 2025 Expectations with Strong Revenue Growth and Narrower Loss
Travere Therapeutics (TVTX) reported strong Q2 2025 results, beating revenue and earnings estimates, driven by FILSPARI sales and milestone payments. Shares rose 2.3% post-earnings. 
Via Chartmill
Travere Therapeutics Reports Second Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.